{"disease":{"id":"cin2","name":"cin2"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04422366","title":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05584332","title":"A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3131,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT04425291","title":"Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1680,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05027776","title":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1348,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05372016","title":"Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05049252","title":"Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04687267","title":"Conservative Management of CIN2 Lesions and Biomarkers Evaluation","phase":"","overall_status":"COMPLETED","enrollment_count":319,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT06147388","title":"Regression of Cervical Precancerous Lesions and Associated Risk Factors","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"General University Hospital, Prague","has_results":false},{"nct_id":"NCT05413811","title":"Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07146152","title":"Empowering Women - Shared Decision Making in Managing Cervical Precancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":138,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03177863","title":"Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age","phase":"NA","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT01543048","title":"Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization","phase":"","overall_status":"TERMINATED","enrollment_count":106,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT03676101","title":"Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}